Vyome Holdings

HIND · NASDAQ

$1.84+$0.00 (+0.00%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $1.84

Latest news

Press releaseOct 5, 8:00 AM ETBusiness Wire
Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
Press releaseSep 14, 8:00 AM ETBusiness Wire
Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
Press releaseAug 25, 8:00 AM ETBusiness Wire
Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
NewsAug 7, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseJul 1, 8:00 AM ETBusiness Wire
Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio
Press releaseMay 28, 8:00 AM ETBusiness Wire
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Press releaseMay 12, 8:00 AM ETBusiness Wire
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Press releaseApr 22, 8:00 AM ETBusiness Wire
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Press releaseApr 6, 8:00 AM ETBusiness Wire
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
NewsMar 26, 5:05 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMar 26, 8:00 AM ETBusiness Wire
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Press releaseFeb 24, 8:00 AM ETBusiness Wire
Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Press releaseFeb 18, 9:00 AM ETBusiness Wire
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Press releaseFeb 11, 7:00 AM ETBusiness Wire
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
NewsFeb 6, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsFeb 4, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
Press releaseFeb 2, 7:00 AM ETBusiness Wire
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Press releaseJan 27, 8:00 AM ETBusiness Wire
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Press releaseDec 22, 8:00 AM ETBusiness Wire
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
NewsDec 19, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
Press releaseDec 8, 8:00 AM ETBusiness Wire
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Press releaseNov 25, 7:00 AM ETBusiness Wire
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Press releaseNov 18, 7:00 AM ETBusiness Wire
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Press releaseNov 4, 9:04 AM ETBusiness Wire
Vyome Holdings Announces Results of Annual Shareholder Meeting
Press releaseSep 29, 7:00 AM ETBusiness Wire
Vyome Holdings Acquires MIT AI Spinout Oculo Health
NewsSep 17, 7:20 AM ET
Market-Moving News for September 17th
Press releaseSep 17, 7:00 AM ETBusiness Wire
Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity
Press releaseSep 9, 8:30 AM ETBusiness Wire
Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies
Press releaseSep 4, 8:30 AM ETBusiness Wire
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity
NewsAug 22, 2:13 PM ETAnthony Noto
Deal Dispatch: Musk-Altman Drama, Ashton Kutcher SoHo House Play And We Pose Questions To Private Equity Pros
Press releaseAug 21, 7:00 AM ETBusiness Wire
Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio
NewsAug 18, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsAug 18, 8:08 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
NewsAug 15, 5:22 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

12 Health Care Stocks Moving In Friday's After-Market Session

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

12 Health Care Stocks Moving In Thursday's After-Market Session

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

12 Health Care Stocks Moving In Friday's Pre-Market Session

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Market-Moving News for September 17th

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Deal Dispatch: Musk-Altman Drama, Ashton Kutcher SoHo House Play And We Pose Questions To Private Equity Pros

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

12 Health Care Stocks Moving In Monday's Intraday Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session